PHENELZINE: ACETYLATOR STATUS AND CLINICAL RESPONSESANDERS GL; RAWLINS MD.1979; BRIT. J. CLIN. PHARMACOL.; GBR; DA. 1979; VOL. 7; NO 5; PP. 451-452; BIBL. 17 REF.Article

COSTS TO CONSIDER WHEN BUYING A SOFTWARE PACKAGESANDERS GL; REED RO; MUNTER P et al.1982; DM, DATA MANAGE.; ISSN 0148-5431; USA; DA. 1982; VOL. 20; NO 9; PP. 18-23; 5 P.Article

THERAPEUTIC DRUG MONITORING: ANTIHYPERTENSIVE AGENTSBATEMAN DN; SANDERS GL; RAWLINS MD et al.1980; THER. DRUG MONIT.; USA; DA. 1980; VOL. 2; NO 2; PP. 127-132; BIBL. 48 REF.Article

LABETALOL, A CROSS-OVER DOUBLE BLIND CONTROLLED TRIALSANDERS GL; ROUTLEDGE PA; RAO JG et al.1978; EUROP. J. CLIN. PHARMACOL.; DEU; DA. 1978; VOL. 14; NO 5; PP. 301-304; BIBL. 11 REF.Article

THE ANREP EFFECT RECONSIDERED = RECONSIDERATION DE L'EFFET ANREPMONROE RG; CAMBLE WJ; LAFARGE CG et al.1972; J. CLIN. INVEST.; U.S.A.; DA. 1972; VOL. 51; NO 10; PP. 2573-2583; BIBL. 28REF.Serial Issue